2-piperidone has been researched along with Alloxan Diabetes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, WK; Kang, WS; Kim, HR; Kim, J; Park, SB | 1 |
| Cervantes-Durán, C; Granados-Soto, V; Murbartián, J; Quiñonez-Bastidas, GN; Rocha-González, HI | 1 |
| Chung, BH; Jin, J; Jin, L; Lim, SW; Yang, CW | 1 |
| Hwang, DM; Jung, E; Kim, DW; Kim, J; Kim, SH; Kwon, OH; Lee, SM; Yim, HJ; Yoon, MK | 1 |
4 other study(ies) available for 2-piperidone and Alloxan Diabetes
| Article | Year |
|---|---|
Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.
Topics: Animals; Antioxidants; Apoptosis; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Male; Oxidative Stress; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Reactive Oxygen Species; Salivary Gland Diseases; Salivary Glands; Salivation; Streptozocin | 2021 |
Analysis of the mechanisms underlying the antinociceptive effect of epicatechin in diabetic rats.
Topics: Analgesics; Animals; Biphenyl Compounds; Catechin; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Female; Glyburide; Hyperalgesia; Indazoles; Methiothepin; Naloxone; NG-Nitroarginine Methyl Ester; Oxadiazoles; Pain Measurement; Piperazines; Piperidones; Pyridines; Quinoxalines; Rats; Spiro Compounds | 2013 |
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Topics: Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Exenatide; Hyperglycemia; Islets of Langerhans; Male; Metformin; Mitochondria; Oxidative Stress; Peptides; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Reactive Oxygen Species; Sirolimus; Venoms | 2016 |
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dogs; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Kinetics; Male; Mice; Piperidones; Pyrimidines; Rats; Substrate Specificity | 2016 |